secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001193125-24-251712
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Q3 revenue $25.2M, net loss $23.7M; UGN-102 PDUFA June 2025; cuts FY revenue view
--------------------------------------------------------------------------------

- JELMYTO Q3 net product revenue $25.2M (+21% YoY from $20.9M).
- Net loss $23.7M ($0.55/share) vs $21.9M ($0.68/share) in Q3 2023.
- NDA for UGN-102 accepted; PDUFA target action date June 13, 2025.
- Full-year 2024 JELMYTO revenue expected below prior guidance low end; still low double-digit YoY growth.
- Cash, equivalents, marketable securities $254.2M as of Sept 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524251712/0001193125-24-251712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524251712/d910412d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-251712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer